Predict your next investment

Venture Capital
missionbaycapital.com

See what CB Insights has to offer

Investments

61

Portfolio Exits

10

Funds

4

Partners & Customers

1

About Mission Bay Capital

Mission Bay Capital, is an independent venture firm focused on making pivotal, early-stage investments in bioscience companies emerging from the University of California. Mission Bay Capital is fueling breakthrough bioscience technologies to meet societyÂâÂÂs challenges while also helping to boost the California economy.

Mission Bay Capital Headquarter Location

953 Indiana Street

San Francisco, California, 94107,

United States

415-240-4970

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Mission Bay Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Mission Bay Capital in 3 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

I

Industrial SynBio

382 items

Synthetic biology focused on replacing industrial and commercial materials.

Latest Mission Bay Capital News

Nitrome’s $38 Million Series A Financing

Apr 24, 2020

Wilson Sonsini Goodrich & Rosati represented Nitrome in the transaction. Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical company developing a platform around a newly identified class of enzymes to target Parkinson’s disease and other age-related disorders, announced that it has closed a Series A financing of $38 million co-led by Sofinnova Partners, a leading European life sciences venture capital firm, and AbbVie Ventures, AbbVie’s corporate strategic venture capital arm, with further participation from the Dementia Discovery Fund, Mission Bay Capital and Alexandria Venture Investments. Henrijette Richter, Ph.D., Managing Partner of Sofinnova Partners, Margarita Chavez, Managing Director of AbbVie Ventures and Jonathan Behr, Ph.D., Partner of the Dementia Discovery Fund, will join Nitrome’s Board of Directors. The financing is intended to support the advancement of Nitrome’s lead program targeting Parkinson’s Disease toward human clinical proof of concept studies and to explore the application of the company’s platform technology in other age-related disorders. Nitrome Biosciences is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. AbbVie Ventures is the corporate venture capital group of AbbVie. The Wilson Sonsini team that advised Nitrome Biosciences in the transaction included Elton Satusky (Picture), Brian Appel, Patricia Swen, and Lenka Schvaigerova.

Mission Bay Capital Investments

61 Investments

Mission Bay Capital has made 61 investments. Their latest investment was in Telo Therapeutics as part of their Seed VC on June 6, 2021.

CBI Logo

Mission Bay Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/22/2021

Seed VC

Telo Therapeutics

$4.2M

Yes

1

3/23/2021

Series A

Asher Bio

$55M

Yes

Boxer Capital, Invus Group, Third Rock Ventures, and Y Combinator

2

2/9/2021

Series A - III

Invenio Imaging

$3.04M

No

1

9/14/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

4/22/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/22/2021

3/23/2021

2/9/2021

9/14/2020

4/22/2020

Round

Seed VC

Series A

Series A - III

Series A

Series A

Company

Telo Therapeutics

Asher Bio

Invenio Imaging

Subscribe to see more

Subscribe to see more

Amount

$4.2M

$55M

$3.04M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Boxer Capital, Invus Group, Third Rock Ventures, and Y Combinator

Sources

1

2

1

10

10

Mission Bay Capital Portfolio Exits

10 Portfolio Exits

Mission Bay Capital has 10 portfolio exits. Their latest portfolio exit was Caribou Biosciences on July 23, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/23/2021

IPO

$991

2

5/27/2021

Acq - Pending

2

3/2/2021

Acquired

2

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

7/23/2021

5/27/2021

3/2/2021

00/00/0000

00/00/0000

Exit

IPO

Acq - Pending

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

2

2

10

10

Mission Bay Capital Fund History

4 Fund Histories

Mission Bay Capital has 4 funds, including Mission Bay Capital III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

9/16/2019

Mission Bay Capital III

Early-Stage Venture Capital

$60M

1

5/2/2015

Mission Bay Capital II

Subscribe to see more

$99M

10

10/28/2009

QB3 Garage

Subscribe to see more

$99M

10

Life Science Fund

Subscribe to see more

$99M

10

Closing Date

9/16/2019

5/2/2015

10/28/2009

Fund

Mission Bay Capital III

Mission Bay Capital II

QB3 Garage

Life Science Fund

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Amount

$60M

$99M

$99M

$99M

Sources

1

10

10

10

Mission Bay Capital Partners & Customers

1 Partners and customers

Mission Bay Capital has 1 strategic partners and customers. Mission Bay Capital recently partnered with Bayer on .

Date

Type

Business Partner

Country

News Snippet

Sources

Partner

Bayer

Germany

Bayer inks startup matchmaking deal with QB3, Mission Bay Capital

Bayer inks startup matchmaking deal with QB3 , Mission Bay Capital .

1

Date

Type

Partner

Business Partner

Bayer

Country

Germany

News Snippet

Bayer inks startup matchmaking deal with QB3, Mission Bay Capital

Bayer inks startup matchmaking deal with QB3 , Mission Bay Capital .

Sources

1

Mission Bay Capital Team

2 Team Members

Mission Bay Capital has 2 team members, including current Managing Partner, Douglas Crawford.

Name

Work History

Title

Status

Douglas Crawford

Managing Partner

Current

Regis B. Kelly

Managing Partner

Current

Name

Douglas Crawford

Regis B. Kelly

Work History

Title

Managing Partner

Managing Partner

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.